Qualigen Therapeutics (NASDAQ:QLGN) Trading Up 21.7% – Should You Buy?

Qualigen Therapeutics, Inc. (NASDAQ:QLGN)’s stock price traded up 21.7% during trading on Wednesday . The company traded as high as $1.45 and last traded at $1.40. 200,031 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,029,491 shares. The stock had previously closed at $1.15.

Qualigen Therapeutics Stock Up 21.7%

The firm’s 50-day simple moving average is $1.63 and its 200-day simple moving average is $2.55. The firm has a market capitalization of $2.37 million, a PE ratio of -0.19 and a beta of 0.24.

Qualigen Therapeutics Company Profile

Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.

Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.